Pathogenic B‐cell receptor signaling in lymphoid malignancies: New insights to improve treatment

DOI Web Site Web Site Web Site 2 Citations
  • Ryan M. Young
    Lymphoid Malignancies Branch, Center for Cancer Research National Cancer Institute, National Institutes of Health Bethesda Maryland
  • James D. Phelan
    Lymphoid Malignancies Branch, Center for Cancer Research National Cancer Institute, National Institutes of Health Bethesda Maryland
  • Wyndham H. Wilson
    Lymphoid Malignancies Branch, Center for Cancer Research National Cancer Institute, National Institutes of Health Bethesda Maryland
  • Louis M. Staudt
    Lymphoid Malignancies Branch, Center for Cancer Research National Cancer Institute, National Institutes of Health Bethesda Maryland

Search this article

Description

<jats:title>Abstract</jats:title><jats:p>Signals emanating from the B‐cell receptor (BCR) promote proliferation and survival in diverse forms of B‐cell lymphoma. Precision medicine strategies targeting the BCR pathway have been generally effective in treating lymphoma, but often fail to produce durable responses in diffuse large B‐cell lymphoma (DLBCL), a common and aggressive cancer. New insights into DLBCL biology garnered from genomic analyses and functional proteogenomic studies have identified novel modes of BCR signaling in this disease. Herein, we describe the distinct roles of antigen‐dependent and antigen‐independent BCR signaling in different subtypes of DLBCL. We highlight mechanisms by which the BCR cooperates with TLR9 and mutant isoforms of MYD88 to drive sustained NF‐κB activity in the activated B‐cell‐like (ABC) subtype of DLBCL. Finally, we discuss progress in detecting and targeting oncogenic BCR signaling to improve the survival of patients with lymphoma.</jats:p>

Journal

Citations (2)*help

See more

Report a problem

Back to top